10-K · February 11, 2026
Viking Therapeutics positions itself as a clinical-stage metabolic and endocrine drug developer focused on VK2735 (GLP-1/GIP dual agonist) and TRß programs (VK2809, VK0214). The 10-K documents multiple positive clinical…
Earnings analysis · 10-Q
VKTX earnings analysis
Filed April 30, 2026 · Our reading of the company's report
The latest report
Viking Therapeutics reported zero revenue for Q1 2026, missing estimates significantly with an actual EPS of -1.37, compared to an estimate of -0.92. Clinical expenses drove losses as the company remains focused on the…
Read full summary
Viking Therapeutics reported zero revenue for Q1 2026, missing estimates significantly with an actual EPS of -1.37, compared to an estimate of -0.92. Clinical expenses drove losses as the company remains focused on the ongoing development of its lead drug candidates, but risks related to trial outcomes persist, impacting investor sentiment.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.37
What stood out
-
Zero Revenue Reported
Viking reported actual revenue of $0.0 for Q1 2026, missing expectations.
-
EPS Miss
The reported EPS was -1.37, deviating from the estimated -0.92.
-
Continued Clinical Focus
Management continues to develop VK2735 and VK2809 despite financial losses.
What to watch
-
Wider Losses
The Q1 EPS loss deepened to -1.37 compared to -1.39 in Q4 2025.
-
Cash Decrease
Cash and cash equivalents decreased to $118.116 million from $165.810 million at year-end 2025.
-
Higher Clinical Expenses
Total clinical study expenses rose to $103.2 million in Q1, contributing to financial strain.
Management's outlook
No changes made to financial guidance; focus remains on trial timelines.
Earlier filings 4
10-Q · October 23, 2025
Viking reported Q3 2025 net loss of $90.8M (basic/diluted loss per share $0.81) on no revenue; R&D spend surged to $89.95M in the quarter driving operating loss of $98.56M. Cash and short-term investments remain large…
10-Q · July 24, 2024
Viking Therapeutics reported no revenue and a Q2 net loss of $22.25 million (basic and diluted net loss per share $0.20) as R&D and G&A ramped. The quarter reflects a significant financing-driven liquidity increase…
10-Q · October 25, 2023
Viking Therapeutics reported a net loss of $22.534 million for Q3 2023, widening from a loss of $15.773 million in Q3 2022. The diluted earnings per share (EPS) came in at $(0.23), slightly below the consensus estimate…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.